Similarly, at 7−18 months follow-up, there were significant reductions in ALT (−45 ± 18 vs. −9 ± 3, p = 0.01) but not AST (2 ± 2 vs. −5 ± 2, p = 0.32) in those with Stage II−III NASH vs. those with Stage 0−I NASH. This evidence concerns the gene GPT and metabolic dysfunction-associated steatohepatitis.